BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 33537004)

  • 1. Regulation of the EGFR Pathway by HSP90 Is Involved in the Pathogenesis of Cushing's Disease.
    Shen Y; Ji C; Jian X; Zhou J; Zhang Q; Qiao N; Zhang Y; Shou X; Zhou X; Ma Z
    Front Endocrinol (Lausanne); 2020; 11():601984. PubMed ID: 33537004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of heat shock protein 90 decreases ACTH production and cell proliferation in AtT-20 cells.
    Sugiyama A; Kageyama K; Murasawa S; Ishigame N; Niioka K; Daimon M
    Pituitary; 2015 Aug; 18(4):542-53. PubMed ID: 25280813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ubiquitin-specific protease 8 inhibitor suppresses adrenocorticotropic hormone production and corticotroph tumor cell proliferation.
    Kageyama K; Asari Y; Sugimoto Y; Niioka K; Daimon M
    Endocr J; 2020 Feb; 67(2):177-184. PubMed ID: 31666445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ubiquitin-Specific Protease 8 Mutant Corticotrope Adenomas Present Unique Secretory and Molecular Features and Shed Light on the Role of Ubiquitylation on ACTH Processing.
    Sesta A; Cassarino MF; Terreni M; Ambrogio AG; Libera L; Bardelli D; Lasio G; Losa M; Pecori Giraldi F
    Neuroendocrinology; 2020; 110(1-2):119-129. PubMed ID: 31280266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lapatinib decreases the ACTH production and proliferation of corticotroph tumor cells.
    Asari Y; Kageyama K; Sugiyama A; Kogawa H; Niioka K; Daimon M
    Endocr J; 2019 Jun; 66(6):515-522. PubMed ID: 30880293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function.
    Gentilin E; Tagliati F; Terzolo M; Zoli M; Lapparelli M; Minoia M; Ambrosio MR; Degli Uberti EC; Zatelli MC
    J Endocrinol; 2013 Sep; 218(3):275-85. PubMed ID: 23814013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Spectrum of USP8 Pathogenic Variants in Cushing's Disease.
    Rebollar-Vega RG; Zuarth-Vázquez JM; Hernández-Ramírez LC
    Arch Med Res; 2023 Dec; 54(8):102899. PubMed ID: 37925320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the ERK pathway for the treatment of Cushing's disease.
    Zhang D; Bergsneider M; Wang MB; Heaney AP
    Oncotarget; 2016 Oct; 7(43):69149-69158. PubMed ID: 27708250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
    Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
    Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.
    Fukuoka H; Cooper O; Ben-Shlomo A; Mamelak A; Ren SG; Bruyette D; Melmed S
    J Clin Invest; 2011 Dec; 121(12):4712-21. PubMed ID: 22105169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease.
    Perez-Rivas LG; Theodoropoulou M; Ferraù F; Nusser C; Kawaguchi K; Stratakis CA; Faucz FR; Wildemberg LE; Assié G; Beschorner R; Dimopoulou C; Buchfelder M; Popovic V; Berr CM; Tóth M; Ardisasmita AI; Honegger J; Bertherat J; Gadelha MR; Beuschlein F; Stalla G; Komada M; Korbonits M; Reincke M
    J Clin Endocrinol Metab; 2015 Jul; 100(7):E997-1004. PubMed ID: 25942478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Corticotroph HDAC and PI3-Kinase in Cushing Disease.
    Zhang D; Damoiseaux R; Babayan L; Rivera-Meza EK; Yang Y; Bergsneider M; Wang MB; Yong WH; Kelly K; Heaney AP
    J Clin Endocrinol Metab; 2021 Jan; 106(1):e232-e246. PubMed ID: 33000123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent gain-of-function USP8 mutations in Cushing's disease.
    Ma ZY; Song ZJ; Chen JH; Wang YF; Li SQ; Zhou LF; Mao Y; Li YM; Hu RG; Zhang ZY; Ye HY; Shen M; Shou XF; Li ZQ; Peng H; Wang QZ; Zhou DZ; Qin XL; Ji J; Zheng J; Chen H; Wang Y; Geng DY; Tang WJ; Fu CW; Shi ZF; Zhang YC; Ye Z; He WQ; Zhang QL; Tang QS; Xie R; Shen JW; Wen ZJ; Zhou J; Wang T; Huang S; Qiu HJ; Qiao ND; Zhang Y; Pan L; Bao WM; Liu YC; Huang CX; Shi YY; Zhao Y
    Cell Res; 2015 Mar; 25(3):306-17. PubMed ID: 25675982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The USP8 mutational status may predict drug susceptibility in corticotroph adenomas of Cushing's disease.
    Hayashi K; Inoshita N; Kawaguchi K; Ibrahim Ardisasmita A; Suzuki H; Fukuhara N; Okada M; Nishioka H; Takeuchi Y; Komada M; Takeshita A; Yamada S
    Eur J Endocrinol; 2016 Feb; 174(2):213-26. PubMed ID: 26578638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.
    Liu NA; Araki T; Cuevas-Ramos D; Hong J; Ben-Shlomo A; Tone Y; Tone M; Melmed S
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2557-64. PubMed ID: 25942479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of trichostatin A on adrenocorticotropic hormone production and proliferation of corticotroph tumor AtT-20 cells.
    Nakada Y; Kageyama K; Sugiyama A; Desaki R; Takayasu S; Niioka K; Murasawa S; Ishigame N; Asari Y; Iwasaki Y; Daimon M
    Endocr J; 2015; 62(12):1083-90. PubMed ID: 26497760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
    Sawai A; Chandarlapaty S; Greulich H; Gonen M; Ye Q; Arteaga CL; Sellers W; Rosen N; Solit DB
    Cancer Res; 2008 Jan; 68(2):589-96. PubMed ID: 18199556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HSP90 inhibitors induce desensitization of EGF receptor via p38 MAPK-mediated phosphorylation at Ser1046/1047 in human pancreatic cancer cells.
    Adachi S; Yasuda I; Nakashima M; Yamauchi T; Yamauchi J; Natsume H; Moriwaki H; Kozawa O
    Oncol Rep; 2010 Jun; 23(6):1709-14. PubMed ID: 20428829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.
    Lang SA; Klein D; Moser C; Gaumann A; Glockzin G; Dahlke MH; Dietmaier W; Bolder U; Schlitt HJ; Geissler EK; Stoeltzing O
    Mol Cancer Ther; 2007 Mar; 6(3):1123-32. PubMed ID: 17363505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.
    Rodrigues LM; Chung YL; Al Saffar NM; Sharp SY; Jackson LE; Banerji U; Stubbs M; Leach MO; Griffiths JR; Workman P
    BMC Res Notes; 2012 May; 5():250. PubMed ID: 22621282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.